Rifampin plus Pyrazinamide for Treatment of Latent Tuberculosis Infection (LTBI)
Audience: Infectious Disease and other healthcare professionals
The Centers for Disease Control and Prevention (CDC) notified healthcare professionals of revised recommendations against the use of rifampin plus pyrazinamide for treatment of latent tuberculosis infection, due to high rates of hospitalization and death from liver injury associated with the combined use of these drugs.
[August 8, 2003 - Letter - CDC]
[August 8, 2003 - MMWR Article - CDC]